Natco Pharma Q1 result: Consolidated net profit falls 28% to ₹481 crore; company announces interim dividend

Its revenue from operations fell by 2.5% YoY to ₹1,329 crore during the quarter under review, as against ₹1,363 crore in the June quarter of FY25, the drug-market said in a regulatory filing.

During the quarter, the business faced pricing pressure in the US product portfolio and incurred increased R&D expenses on account of high-value projects, it stated.

The pharmaceuticals segment contributed ₹1,294 crore in Q1FY26, falling 3.93% YoY from ₹1,347 crore in the year-ago period. Furthermore, the company’s agrochemicals vertical grew 118.75% YoY to ₹35 crore during the reporting quarter, as against ₹16 crore in Q1FY25.

The drug-maker’s EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹632.7 crore with margins at 45.5%.

Board declares interim dividend

Natco Pharma’s board of directors also declared an interim dividend of ₹2 per equity share with a face value of ₹2 each, at a 100% rate for the 2025-26 financial year.

It also fixed August 19, 2025, as the record date. The company will start making the interim dividend payments from August 26, 2025.

Natco Pharma stock performance

Shares of Natco Pharma closed 1.33% lower at ₹887.8 apiece on the National Stock Exchange (NSE) on Tuesday, following the result announcement.

The stock declined 2.5% over the previous week and 6.83% since the beginning of August. It gained 16.01% in the June FY26 quarter but lost 35.97% on a year-to-date basis.

Natco Pharma has a total market capitalisation of ₹15,901.37 crore, as of August 12, 2025, as per data on the NSE.